ECOG-ACRIN/NRG Joint Study:A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, the INSPIRE Study
Principal Investigator
Abhishek Solanki,
Status
Closed to Accrual
Date Opened To Accrual
August 25 2020
Date Closed to Accrual
October 02 2023
Disease Site
Genitourinary [GU]
Bladder
Phase
II
Developmental Therapeutics
Yes
Primary Objective
To compare the clinical complete response rate [cCR] after chemoRT with or without MEDI4736 (durvalumab) in node-positive bladder cancer patients.
NOTE:
This is a Joint ECOG/ACRIN & NRG Oncology trial, with ECOG-ACRIN as the lead group for trial conduct. NRG Oncology institutions can credit NRG for their case accrual.
ECOG-ACRIN Study Chair: Monika Joshi, MD, MRCP
Patient Population
Patient with histologically proven pure or mixed urothelial cancer of the bladder (any T, N1-2 M0).
Target Accrual
114
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.